Schrödinger, Inc. Overview
Pro stress-test →Schrödinger develops a physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates a dual-engine business model combining high-margin software licensing with drug discovery collaborations, positioning itself at the intersection of enterprise software and biotech innovation.
Strategic Profile
Pro stress-test →The platform is designed to accelerate R&D by predicting molecular properties, reducing the time and cost required to bring new products to market. Once integrated into large pharma's R&D workflow, the platform becomes a mission-critical tool with high switching costs.
Competitive Landscape
Pro stress-test →Schrödinger stands at the confluence of biotechnology, materials science, and enterprise software, having moved beyond traditional silos to create a hybrid enterprise model. Key competitors include computational chemistry software providers (Schrödinger, Certara), biotech platforms (Tempus AI, Veeva Systems), and CRO/discovery services competitors.
Industry Context
Schrödinger, Inc. operates in Computational Science / Biotech Software.
Key facts
Founded: 1990 · Headquarters: New York, NY · Revenue: $255.9M (2025) · Market cap: $1.46B